Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
← catalyst calendarSponsored by Vanda Pharmaceuticals (industry) · VNDA — their whole pipeline →.
Phase
Phase 4
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
100estimated
Sites
9
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-05-24 | actual | When the study began enrolling |
| Primary completion | 2026-03-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-11-30 | estimated | The whole study's end, after follow-up |
| First posted | 2022-12-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-03-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Schizophrenia
- Bipolar I Disorder
Intervention
- Drug: Iloperidone — also filed as VYV-683, FANAPT
Primary outcome
what the primary-completion date above is the date OFNumber of participants with treatment-emergent adverse events (TEAEs) in the treatment period.
measured 1 year
Permalink · VNDA's whole pipeline · Catalyst calendar · Every registered study · What changed